Prior systemic therapy for castration-sensitive prostate cancer will determine subsequent therapy used for mCRPC. Continue androgen-deprivation therapy for patients with mCRPC indefinitely. Early ...

Exclusion criteria were prostate cancer diagnosis > 6 months before study entry, previous therapy for prostate cancer other than biopsy or transurethral resection, > 12 weeks of hormone therapy for ...